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S100B protein levels in patients admitted to an emergency service 
due to seizures
Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi
Fatma SARI DOĞAN, Arzu DENİZBAŞI  ALTINOK, Özge ECMEL ONUR, Özlem GÜNEYSEL, Haldun AKOĞLU
Introduction
Epilepsy , a common neurological disorder throughout the 
world, is also an important public health issue associated 
with a large economical burden due to the requirement of 
lifetime drug treatment and concomitant diseases. Epileptic 
seizures which occur as partial or generalized forms may be 
life-threatening[1]. Almost 28% of all patients with epilepsy 
require emergency treatment annually[2]. Seizures may 
cause severe and persistent damage in the central nervous 
system (CNS). Several biochemical markers are used for 
the assessment of this damage. S100 proteins are among the 
markers investigated for this purpose.
S100B is a multigenic family of calcium-modulated 
proteins of the EF-hand type expressed in vertebrates. 
Members of this protein family modulate enzyme activities 
by interacting with numerous effector proteins. They affect 
the structural dynamics of the cytoskeleton, modulate 
Fatma Sarı Doğan ()
Department of Emergency Medicine, Göztepe Training and Research Hospital, 
İstanbul, Turkey 
e-mail: fatmasdogan@gmail.com
Arzu Denizbaşı Altınok, Özge Ecmel Onur
Department of Emergency Medicine,  School of Medicine, Marmara University,   
İstanbul, Turkey
Özlem Güneysel, Haldun Akoğlu
Department of Emergency Medicine, Lütfü Kırdar Training and Research 
Hospital,  İstanbul, Turkey
Submitted/Gönderme: 29.01.2013 - Acepted/Kabul: 18.03.2013
Marmara Medical Journal 2013; 26:90-3
DOI: 10.5472/MMJ.2013.02515.1
ABSTRACT
Objectives: Various levels of dysfunction and damage can occur in 
the central nervous system of patients experiencing seizures. It is 
known that these impairments can be assessed by measurement of 
biochemical markers. S100B proteins have been extensively studied 
in recent years. We have assessed  whether there is a change in 
serum S100B protein levels during seizures which lead to cerebral 
hypoperfusion and/or hypoxia.
Patients and Methods: A total of 56 patients admitted to 
an emergency service due to seizures and more than 18 years of 
age  were included in the study. The control group consisted of 
20 patients who were admitted to the emergency service due to 
complaints other than seizures. 
Results: There was a significant difference between the groups 
in terms of gender, hemoglobin levels and S100B levels, whereas 
there was no significant difference in terms of glucose, sodium and 
potassium levels. The S100B levels were significantly lower in the 
patient group compared to the control group. Hemoglobin levels 
was significantly lower in the control group compared to the patient 
group.
Conclusion: Serum S100B protein concentration was found to 
be significantly lower in patients compared to controls.
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ÖZET 
Amaç: Nöbet geçiren hastalarda santral sinir sisteminde 
farklı düzeylerde disfonksiyon ve hasar oluşabilmektedir. Bu 
hasarlanmaların biyokimyasal belirteçlere bakılmak suretiyle 
değerlendirilebileceği bilinmektedir. Son yıllarda giderek artan bir 
şekilde “beyine özel göstergeler” araştırılmaktadır. Bu çalışmada 
serebral hipoperfüzyon ve/veya hipoksiye neden olan nöbet 
durumlarında serum S100B protein düzeylerinde değişiklik oluşup 
oluşmadığının belirlenmesi amaçlanmıştır. 
Hastalar  ve Yöntem: Acil servise nöbet şikayetiyle başvuran 
≥18 yaşında 56 hasta çalışmaya alınmıştır. Kontrol grubunu nöbet 
dışı bir şikayetle acil servise başvuran 20 hasta oluşturmuştur.
Bulgular: Gruplar arasında cinsiyet, hemoglobin değerleri 
ve S100B proteini açısından  anlamlı olarak fark bulunmuştur. 
Bunun yanında glukoz, sodyum ve potasyum değerleri açısından 
gruplar arasında anlamlı olarak bir fark yoktur. Hasta grubu S100B 
değerleri, kontrol grubuna göre istatistiksel açıdan anlamlı olarak 
düşük  bulunmuştur. Hemoglobin değerleri ise,  kontrol grubunda, 
hasta grubuna göre anlamlı olarak düşük bulunmuştur.
Sonuç: Hasta grubu serum S100B protein konsantrasyonu, 
kontrol grubundan anlamlı olarak düşük bulunmuştur. 
Anahtar Kelimeler: Nöbet, S100B protein, Acil
91
Marmara Medical Journal 2013; 26:90-3
Doğan et al.
S100B protein levels in seizures
ages of patient and control groups were similar. Significant 
differences were noted between the groups in terms of 
gender, hemoglobin level and S100B levels.  The S100B 
levels were significantly lower in the patient group compared 
to the control group. Hemoglobin levels were significantly 
lower in the control group compared to the patient group. 
No significant differences were noted between the groups in 
terms of glucose, sodium and potassium levels.
Discussion
In recent years, S100B protein has been largely focused 
on as a biochemical marker of cerebral disorders. Increased 
serum S100B protein level may reflect either glial damage or 
Table I. Characteristics of patient and control groups
Patient Group 
(n=56)
Control Group 
(n=20)
p
Gender
 Male 32 (57.1) 6 (30.0)
0.037
 Female 24 (42.9) 14 (70.0)
Age (years) 55.46±21.08 60.65±15.68 0.255
S100B (ng/L) 42.75±53.51 51.05±44.27 0.006
Glucose (mg/dL) 115.05±29.97 124±32.01 0.264
Sodium (mEq/L) 137.48±6.88 137.25±8.70 0.904
Potassium (mEq/L) 4.17±0.60 4.24±0.65 0.690
Hemoglobin (g/dL) 12.94±2.08 11.37±1.87 0.005
Results are expressed as either n (%) or mean±standard deviation.
cell growth and differentiation and establish calcium 
homeostasis [3-5]. S100B is a homodimer protein which is 
primarily released from astrocytes, is found in large amounts 
in the CNS and has autocrine and paracrine effects of glia 
cells neurons and microglia [5, 6]. Release of S100B from 
astrocytes occurs under metabolic stress conditions such as 
oxygen and glucose deprivation7.
Following brain injury, S100B transferred to the 
cerebrospinal fluid (CSF) and then to the circulation [3, 4]. 
High CSF and serum levels of S100B have been reported in 
Alzheimer’s disease, stroke, traumatic brain injury and acute 
subarachnoid hemorrhage [8-11]. 
Central nervous system dysfunction and injury occurs in 
patients sustaining generalized seizures. 
This study assessed serum S100B protein levels in 
patients admitted  to an emergency service due to seizures.
Patients and Methods
Study Design
The present study was designed as a prospective controlled 
study. The study was approved by the Ethical Board of 
Marmara University,  School of Medicine and all patients 
provided informed consent.
Study Setting and Population
The study was conducted in the Hospital of the Marmara 
University, Faculty of Medicine. Adult patients (≥18 years 
of age) admitted  to the emergency service due to seizures 
were included in the study. Subjects with a history of central 
nervous system trauma, cerebrovascular events, malignant 
melanoma or an intracranial mass and those subjects who 
were diagnosed as a conversion disorder or syncope at the 
time of admission were excluded.
Totally 234 patients were admitted to the emergency unit 
due to seizures during the one-year study period. During 
the assessment performed at time of emergency admission, 
it was noted that the primary complaint was not a seizure 
in 20 patients. Another 65 patients were excluded due to 
an intracranial mass, 70 patients due to a cerebrovascular 
accident (CVA) and 21 patients due to head injury. A total of 
58 patients were included, but 2 patients were also excluded 
because appropriate blood samples could not be obtained. 
Data from 56 patients were included in final analysis. The 
control group consisted of 20 patients who had been admitted 
to the emergency service due to complaints other than 
seizures.
Study protocol
Demographic innormation about the patients was recorded 
and blood samples were obtained for the measurement of 
serum S100B protein level in addition to a complete blood 
count and routine biochemistry tests. All patients underwent 
a neurological examination and were treated accordingly 
following necessary radiological evaluations.
The venous blood samples collected for serum S100B 
protein level measurement were immediately centrifuged and 
serum samples were stored at -40ºC. After drawing the serum 
samples, a S100B protein level analysis was performed using 
a CanAg S100BB EIA (Fujirebio Diagnostics) kit according 
to the instructions provided by the manufacturer.
Key Outcome Measures
Serum S100B protein levels of patients and controls were 
compared.
Data Analysis
Data were analyzed by the Statistical Package for the 
Social Sciences (SPSS) for Windows (version 15.0; SPSS 
Inc., Chicago, IL, USA). Between-group comparisons were 
performed by the Mann Whitney U test or by the independent 
samples t-test depending on their distribution. The statistical 
significance level was set as p<0.05.
Results
Men constituted 57.1% of patients (n=56) and 30% of control 
subjects (n=20) included in the study. Characteristics of 
patient and control groups are presented in Table I. The mean 
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astrocytic reactions to neural injury. Serum S100B protein 
levels increase after trauma and after stroke. In previous 
studies, serum S100B protein level was associated with 
severity of trauma and disease prognosis [3-7].
As a marker of  epilepsy  S100B protein has been studied 
in a few studies which have reported controversial results 
[12-20]. It is not clear whether S100B protein has a role in 
the pathophysiology of epilepsy or whether S100B has an 
antiepileptic action . In our study we found that serum S100B 
levels in patients suffering from seizures were significantly 
lower compared to the control group. 
In our study, in order to elucidate the role of S100B 
protein in epileptogenesis, knockout (KO) and wild-
type (WT) mice have been compared and the results have 
supported the hypothesis that astrocytes have some kind of 
an antiepileptic activity through S100B21. In another study, 
a rat seizure model using pentylenetetrazol (PTZ) has been 
used and significant increases in CSF S100B levels have been 
noted between 10-360 minutes after the seizures returning  to 
control levels at 24 hours [12].
The mean age of the patient group was 55.46±21.08 
years in our study. In another study, Leutmezer et al. 
prospectively investigated changes in postictal serum S100B 
protein concentration in 10 patients with mesial temporal 
lobe epilepsy (TLE) 16 . The mean age in this study was 12 
(range: 7-22) years and 8 out of 10 samples from subjects 
were found to have high serum S100B concentration and no 
statistically significant changes were noted16but this finding 
could not be explained in this study. 
Portela et al. [22] have reported a negative correlation 
between age and serum S100B concentration. Thus, the 
difference between our results and the results of Leutmezer 
et al. 16 might be due to the difference in mean age of the two 
patient groups. Our age group was older than Leutmezer’s 
group.
Serum S100 protein concentration was prospectively 
measured in 9 adult patients following tonic clonic seizures at 
5 minutes, 6 hours, 24 hours, 48 hours by a radioimmunoassay 
(RIA) method and no statistically significant differences were 
found compared to the control group [15]. It was concluded 
that serum S100 protein levels cannot be considered as a 
promising marker to indicate brain dysfunction following 
seizures [15]. We used an enzyme immunoassay (EIA) 
method to measure serum S100B protein levels, which were 
found to be significantly lower in patients who were suffering 
from seizures. However, as each study included control 
groups, the discrepancy of the results cannot be attributed to 
the difference in measurement method (RIA or EIA).
There were more men in the patient group in our study. 
It has been suggested in some studies that the higher 
prevalence of epilepsy in men can be associated with their 
greater involvement in social life and consequently greater 
trauma [23]. 
In a study conducted in patients with drug-resistant 
partial seizures, Otto et al. have found in contrast to our 
findings that there was a statistically significant increase 
in serum S100 concentration following seizures, and that 
serum S100 concentration reached a peak level at the initial 
60 minutes after the seizure and then gradually decreased 
in the following hours [13]. Blood samples were obtained 
at time of admission to the emergency service in our study. 
While some patients were suffering from seizures during 
their assessment in the emergency service, others had been 
admitted in the postictal period and the exact time of seizures 
was not  recorded in the patient’s history. The difference in 
time of sampling may explain the difference of our results 
and those reported by Otto et al. [13].
High S100B levels noted in previous studies might have 
resulted from an increase due to a passive leak related to acute 
seizures or active release to limit the seizure. No significant 
difference has have been noted in S100B levels of patient 
and control groups in some of the studies [14-16]. The lower 
S100B level found in our study may be due to the depletion 
and therefore reduction of S100B which is actively released 
for protection following seizure.
Limitations
In the present study, the diagnosis of seizure was 
based on history and neurological examination and not by 
electroencephalography (EEG), and this may be considered 
as a limitation. The control group was not selected from 
healthy adults and was formed by patients admitted  to the 
emergency service due to complaints other than seizures. 
It should be noted however that pathologies that have been 
previously reported to cause an increase in S100B level were 
all excluded. Thus, we do not believe that this might have led 
to any bias.
Conclusion
In conclusion, the serum S100B protein concentration has 
been found to be statistically significantly lower in patients 
suffering from seizures compared to controls; however, 
this result  has no clear-cut explanation. Further research is 
warranted in order to clarify the role of S100B released from 
astrocytes in seizure mechanisms and to determine whether it 
acts as a neuroprotective or neurodegenerative agent. Future 
studies are required to provide a definitive statement for 
serum S100B levels in the postictal period in patients with 
seizures as “reduced, not changed or increased” and to use 
serum S100B protein level as a biomarker in patients with 
seizures. 
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